Form 4: Nuvalent Director Matthew Shair Sells Shares Under 10b5-1 Trading Plan

Director Matthew Shair of Nuvalent, Inc. sold a portion of his Class A Common Stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Matthew Shair, a director at Nuvalent, Inc., sold shares of Class A Common Stock on December 23, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 21, 2023.
• A total of 1,409 shares were sold at a weighted average price of $83.62, with individual prices ranging from $82.96 to $83.95.
• An additional 591 shares were sold at a weighted average price of $84.17, with individual prices ranging from $83.97 to $84.60.
• Following these transactions, Mr. Shair directly owns 1,427,197 shares and indirectly owns 220,522 shares through the Matthew D. Shair 2021 Irrevocable Family Trust.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading under a pre-arranged plan, which is neither positive nor negative in itself. It is a neutral event.

Risks

• Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

This is a routine disclosure of insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 plan indicates that the sales were pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice for corporate insiders to avoid accusations of trading on non-public information.
• Similar filings are common across all publicly listed companies, including biotech firms like Nuvalent, such as those from companies like Amgen, Gilead, and Regeneron.

Stakeholder Impact

• The sales may have a minor impact on shareholder sentiment, but the pre-planned nature of the transactions should mitigate any significant concerns.

Key Dates

Keywords

insider trading, Form 4, Matthew Shair, Nuvalent, stock sale, 10b5-1 plan, director, NUVL